參考文獻(xiàn)

1.中國(guó)醫(yī)師協(xié)會(huì)皮膚科醫(yī)師分會(huì)帶狀皰疹專(zhuān)家共識(shí)工作組,國(guó)家皮膚與免疫疾病臨床醫(yī)學(xué)研究中心. 中國(guó)帶狀皰疹診療專(zhuān)家共識(shí)(2022版)[J]. 中華皮膚科雜志,2022,12:1033-1040.

2.中國(guó)醫(yī)療保健國(guó)際交流促進(jìn)會(huì)皮膚科分會(huì). 帶狀皰疹疫苗預(yù)防接種專(zhuān)家共識(shí)[J]. 中華醫(yī)學(xué)雜志,2022,102(8):538-543.

3.LU L, SUO L, LI J, et al. A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China [J]. Hum Vaccin Immunother, 2018, 14(11): 2632-5.

4.Dworkin R H , Johnson R W , Breuer J ,et al.Recommendations for the management of herpes zoster.[J].Clinical Infectious Diseases An Official Publication of the Infectious Diseases Society of America, 2007, 44 Suppl 1(Supplement 1):S1.DOI:10.1086/510206.

5.Marra, F., et al., Risk Factors for Herpes Zoster Infection: A Meta-Analysis. Open Forum Infect Dis, 2020. 7(1): p. ofaa005.

6.Torcel-Pagnon, L., et al., Impact of Underlying Conditions on Zoster-Related Pain and on Quality of Life Following Zoster. J Gerontol A Biol Sci Med Sci, 2017. 72(8): p. 1091-1097.

*騰訊醫(yī)典內(nèi)容團(tuán)隊(duì)出品